Galapagos NV expected to post a loss of €3.93 a share - Earnings Preview

Lakefront Biotherapeutics NV

20/02/2024 11:02

* Galapagos NV  GLPG.AS   is expected to show a fall in
quarterly
revenue when it reports  results on February 22 for the period
ending December 31 2023
    * The Malines (mechelen) Antwerpen-based  company is
expected to
report a 14.3% decrease in revenue to €81.505 million from
€95.12 million a year ago, according to the mean estimate from 2
analysts, based on LSEG data. (Majority sales represents Total
Revenue)
    * ​LSEG's mean analyst estimate for Galapagos NV is for a
loss of
€3.93 per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 10
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Galapagos
NV is
€40.00​, above​ its last closing price of €36.81. ​​​

Previous quarterly performance (using preferred earnings measure
in euros). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.93       -0.96      0.39      Beat    140.6
 Jun. 30 2023  -0.71       -0.83      0.08      Beat    109.6
                                      0.35              ​
 Dec. 31 2022  -0.53       -0.53      -3.16     Missed  -490.7
 ​​Sep.        -0.80       -0.80      0.33      Beat    141.3
 30 2022                                                
 Jun. 30 2022  -0.87       -0.82      -0.29     Beat    64.5​
 Mar. 31 2022  -1.06       -1.06      -0.20     Beat    81.1
 Dec. 31 2021  -0.75       -0.64      0.25      Beat    138.9
 This summary was machine generated February 20 at 11:02 GMT. 
All figures in euros unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)